July 19, 2022 - Several years ago, scientists studying aging at the Harvard Stem Cell Institute used a somewhat Frankensteinian technique known as parabiosis — surgically joining a young mouse and an old mouse so that they share blood — to see what would happen to the heart and skeletal muscle tissue.
Read More →
May 5, 2022 - Dr. Mark Allen, the co-founder and CEO of Elevian, tells us their experience and about selecting their first target: stroke.
Listen Here (interview begins at 34:35) —>
Read MoreSep. 16, 2021- Elevian, an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, today announced that it raised $40 million in an oversubscribed Series A round led by Prime Movers Lab. The funding will enable Elevian to submit an investigational new drug application, scale manufacturing and complete Phase 1 clinical trials for its lead indication of stroke recovery.
Read MoreNov. 24, 2020 - Elevian, an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, today announced the closing of a $15 million equity financing. Proceeds from the equity financing will enable Elevian to advance recombinant GDF11 (rGDF11) toward the clinic to treat stroke and other age-related diseases.
Read MoreJan. 5, 2019 - Elevian develops regenerative medicines, with the potential to treat and prevent many age-related diseases and extend healthy lifespan, targeting a fundamental mechanism of aging: regenerative capacity, our body’s ability to heal itself, which declines with age.
Read More